Name | Number of supported studies | Average coverage | |
---|---|---|---|
CD8-positive, alpha-beta T cell | 5 studies | 31% ± 9% | |
epithelial cell | 4 studies | 29% ± 9% | |
natural killer cell | 4 studies | 26% ± 7% | |
CD4-positive, alpha-beta T cell | 4 studies | 42% ± 6% | |
hematopoietic precursor cell | 3 studies | 23% ± 9% | |
erythroblast | 3 studies | 40% ± 19% | |
B cell | 3 studies | 23% ± 2% | |
T cell | 3 studies | 21% ± 6% | |
effector CD8-positive, alpha-beta T cell | 3 studies | 24% ± 3% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
liver | 3 studies | 33% ± 22% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
uterus | 98% | 142.90 | 166 / 170 | 97% | 25.87 | 447 / 459 |
ovary | 97% | 173.14 | 175 / 180 | 97% | 16.99 | 418 / 430 |
bladder | 100% | 159.67 | 21 / 21 | 94% | 22.34 | 474 / 504 |
intestine | 96% | 340.27 | 930 / 966 | 97% | 28.17 | 511 / 527 |
breast | 97% | 184.65 | 444 / 459 | 95% | 17.09 | 1057 / 1118 |
esophagus | 90% | 385.87 | 1305 / 1445 | 100% | 24.15 | 183 / 183 |
skin | 98% | 971.83 | 1768 / 1809 | 90% | 16.30 | 423 / 472 |
stomach | 82% | 196.61 | 294 / 359 | 97% | 24.26 | 278 / 286 |
lung | 89% | 173.26 | 512 / 578 | 89% | 18.33 | 1029 / 1155 |
brain | 96% | 289.36 | 2545 / 2642 | 80% | 11.23 | 564 / 705 |
adrenal gland | 93% | 193.59 | 239 / 258 | 60% | 5.52 | 137 / 230 |
prostate | 98% | 150.76 | 239 / 245 | 50% | 3.42 | 251 / 502 |
kidney | 80% | 115.61 | 71 / 89 | 35% | 2.47 | 319 / 901 |
pancreas | 27% | 26.73 | 90 / 328 | 76% | 7.48 | 135 / 178 |
lymph node | 0% | 0 | 0 / 0 | 100% | 21.91 | 29 / 29 |
tonsil | 0% | 0 | 0 / 0 | 100% | 30.25 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 8.33 | 1 / 1 |
spleen | 100% | 460.11 | 240 / 241 | 0% | 0 | 0 / 0 |
thymus | 77% | 87.82 | 506 / 653 | 22% | 4.05 | 131 / 605 |
adipose | 94% | 144.58 | 1137 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 93% | 124.74 | 1240 / 1335 | 0% | 0 | 0 / 0 |
heart | 72% | 88.72 | 619 / 861 | 0% | 0 | 0 / 0 |
liver | 30% | 66.17 | 67 / 226 | 42% | 3.92 | 170 / 406 |
peripheral blood | 69% | 1316.50 | 638 / 929 | 0% | 0 | 0 / 0 |
muscle | 55% | 48.44 | 440 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 16% | 0.89 | 13 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0042177 | Biological process | negative regulation of protein catabolic process |
GO_0000070 | Biological process | mitotic sister chromatid segregation |
GO_0000132 | Biological process | establishment of mitotic spindle orientation |
GO_0051301 | Biological process | cell division |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0090267 | Biological process | positive regulation of mitotic cell cycle spindle assembly checkpoint |
GO_1904667 | Biological process | negative regulation of ubiquitin protein ligase activity |
GO_0045930 | Biological process | negative regulation of mitotic cell cycle |
GO_0007094 | Biological process | mitotic spindle assembly checkpoint signaling |
GO_0051660 | Biological process | establishment of centrosome localization |
GO_0000922 | Cellular component | spindle pole |
GO_0072686 | Cellular component | mitotic spindle |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0000776 | Cellular component | kinetochore |
GO_0005654 | Cellular component | nucleoplasm |
GO_0033597 | Cellular component | mitotic checkpoint complex |
GO_0044615 | Cellular component | nuclear pore nuclear basket |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_1990728 | Cellular component | mitotic spindle assembly checkpoint MAD1-MAD2 complex |
GO_0005634 | Cellular component | nucleus |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0005515 | Molecular function | protein binding |
Gene name | MAD2L1 |
Protein name | Mitotic arrest deficient 2 like 1 Mitotic spindle assembly checkpoint protein MAD2A (HsMAD2) (Mitotic arrest deficient 2-like protein 1) (MAD2-like protein 1) |
Synonyms | MAD2 |
Description | FUNCTION: Component of the spindle-assembly checkpoint that prevents the onset of anaphase until all chromosomes are properly aligned at the metaphase plate . In the closed conformation (C-MAD2) forms a heterotetrameric complex with MAD1L1 at unattached kinetochores during prometaphase, the complex recruits open conformation molecules of MAD2L1 (O-MAD2) and then promotes the conversion of O-MAD2 to C-MAD2 . Required for the execution of the mitotic checkpoint which monitors the process of kinetochore-spindle attachment and inhibits the activity of the anaphase promoting complex by sequestering CDC20 until all chromosomes are aligned at the metaphase plate . . |
Accessions | D6RJE3 ENST00000333047.9 [Q13257-2] ENST00000296509.11 [Q13257-1] Q13257 ENST00000504707.1 |